Type 1 Diabetes Mellitus research hub
5 indexed studies · 1 currently recruiting
- active not recruitingPHASE3
The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.
This study looks into whether a daily tablet called fenofibrate can help protect the eyes of adults with Type 1 diabetes. It aims to see if this medicine can prevent or slow down eye damage, which is a common problem for people with diabetes.
Australia · Hong Kong · New Zealand - recruitingNA
Is Community Based Monitoring of Diabetic Maculopathy and Pre-proliferative Diabetic Retinopathy Safe?
This study looks at whether opticians in your local area can help check for eye problems caused by diabetes, using special scans. It aims to make it easier to get checked and reduce hospital visits, while making sure it's safe and effective.
United Kingdom - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A phase 1, open-label trial in healthy subjects and in subjects with diabetes investigating pharmacokinetics, tolerability, safety, and food effect following single and multiple dosing of danegaptide
This study is testing a new medicine called danegaptide. It looks at how the body handles the medicine, if it's safe, and whether food affects it. This is for people with diabetes and healthy volunteers to help understand how this medicine might one day treat diabetic retinopathy.
Sweden - authorisedTherapeutic exploratory (Phase II)
Open-label, safety, tolerability and proof of concept study to evaluate the use of ANXV (recombinant human Annexin A5 protein) in the treatment of patients with either Diabetic Retinopathy or recent onset Retinal Vein Occlusion
This study is testing a new medicine, ANXV, for people with certain eye conditions like diabetic eye disease or recent blood clots in the eye, to see if it's safe and how well it works. It's an early stage trial to understand the medicine better.
Germany - active not recruitingPHASE2
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
This study is testing a new medicine, BI 764524, for people with an eye condition called diabetic retinopathy. It aims to see if it improves their vision and how often it should be given.
United States · Germany · Hungary